Oncotarget

Research Papers:

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction

Gerd Jomrich, Marlene Hollenstein, Maximilian John, Andreas Baierl, Matthias Paireder, Ivan Kristo, Aysegül Ilhan-Mutlu, Reza Asari, Matthias Preusser and Sebastian F. Schoppmann _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:6968-6976. https://doi.org/10.18632/oncotarget.24087

Metrics: PDF 554 views  |   HTML 883 views  |   ?  


Abstract

Gerd Jomrich1, Marlene Hollenstein1, Maximilian John1, Andreas Baierl2, Matthias Paireder1, Ivan Kristo1, Aysegül Ilhan-Mutlu3, Reza Asari1, Matthias Preusser3 and Sebastian F. Schoppmann1

1Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), 1090 Vienna, Austria

2Department of Statistics and Operations Research, University of Vienna, 1090 Vienna, Austria

3Department of Medicine 1, Medical University of Vienna, Comprehensive Cancer Center (CCC), 1090 Vienna, Austria

Correspondence to:

Sebastian F. Schoppmann, email: sebastian.schoppmann@meduniwien.ac.at

Keywords: adenocarcinoma of the esophagogastric junction; neoadjuvant therapy; mGPS; inflammation; malnutrition

Received: August 14, 2017     Accepted: January 02, 2018     Published: January 08, 2018

ABSTRACT

The modified Glasgow Prognostic Score (mGPS) combines the indicators of decreased plasma albumin and elevated CRP. In a number of malignancies, elevated mGPS is associated with poor survival. Aim of this study was to investigate the prognostic role of mGPS in patients with neoadjuvantly treated adenocarcinomas of the esophagogastric junction 256 patients from a prospective database undergoing surgical resection after neoadjuvant treatment between 2003 and 2014 were evaluated. mGPS was scored as 0, 1, or 2 based on CRP (>1.0 mg/dl) and albumin (<35 g/L) from blood samples taken prior (preNT-mGPS) and after (postNT-mGPS) neoadjuvant therapy. Scores were correlated with clinicopathological patients’ characteristics. From 155 Patients, sufficient data was available. Median follow-up was 63.8 months (33.3–89.5 months). In univariate analysis, Cox proportional hazard model shows significant shorter patients OS (p = 0.04) and DFS (p = 0.02) for increased postNT-mGPS, preNT-hypoalbuminemia (OS: p = 0.003; DFS: p = 0.002) and post-NT-CRP (OS: p = 0.03; DFS: p = 0.04). Elevated postNT-mGPS and preNT-hypoalbuminemia remained significant prognostic factors in multivariate analysis for OS (p = 0.02; p = 0.005,) and DFS (p = 0.02, p = 0.004) with tumor differentiation and tumor staging as significant covariates. PostNT-mGPS and preNT-hypoalbuminemia are independent prognostic indicators in patients with neoadjuvantly treated adenocarcinomas of the esophagogastric junction and significantly associated with diminished OS and DFS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24087